First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Hisao ImaiTakashi KijimaKoichi AzumaKazuma KishiHaruhiro SaitoTeppei YamaguchiJunko TanizakiYasuto YoneshimaKohei FujitaSatoshi WatanabeSatoru KitazonoTatsuro FukuharaOsamu HatajiYukihiro ToiHideaki MizutaniYusuke HamakawaMakoto MaemondoTomoyuki OhsugiKeisuke SuzukiHidehito HorinouchiYuichiro OhePublished in: Japanese journal of clinical oncology (2024)
LIGHT-NING offers valuable insights into combination immunotherapy for untreated patients with stage IV or recurrent non-small cell lung cancer in Japanese real-world settings.
Keyphrases